? 永利真人大全,澳门金沙真人真钱视频_武夷山囱晃信息科技有限公司 永利真人大全欢迎您!

发现

VASCEPA®

有经验的

在脂质科学中

投资者

关系

VASCEPA®

永利真人大全:生僻字


改善心血管健康的疗法

阿玛林公司 plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. 阿玛琳’s lead product, VASCEPA® (icosapent ethyl) capsules, is available by prescription in the United States and an increasing number of other countries.

The History of VASCEPA®


Development of VASCEPA® leveraged 阿玛琳’s extensive experience in the therapeutic benefits of polyunsaturated fatty acids and lipid science. The development of VASCEPA® challenged previously established understandings of the treatment of complex disease states and created an important new drug with the potential to significantly improve patient care for millions of patients. The use of VASCEPA® is supported by over 200 issued patents worldwide. VASCEPA® was designated by FDA as a new chemical entity in recognition of the drug’s novel single active ingredient. Similar designations have also been granted to VASCEPA®’s active ingredient in other jurisdictions internationally.

更多


阿玛琳 Announces Plans to Maximize Blockbuster Potential of VASCEPA? (icosapent ethyl) in Europe 更多

阿玛琳 Reports Second Quarter 2020 Financial Results and Provides Update on Operations 更多

符号:
AMRN (NASDAQ)
引用:
$6.77
更改:
+0.29
日期:
4:00 PM on Aug 3, 2020
(latest end of day stock price)
Investor
Executive
Career
联系

阿玛琳
公司

therapeutics to improve
心血管健康。

You may automatically receive 阿玛林公司 plc financial information by email.


点击订阅

友情链接: 搜狗   百度   神马   永利真人大全   baiduxml